Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients

AIDS Research and Human Retroviruses

Volumn 22, Issue 4, 2006, Pages 321-329

  Bonjoch, Anna ^a,m   Paredes, Roger ^a   Domingo, Pere ^b   Cervantes, Manel ^c   Pedrol, Enric ^d   Ribera, Esteve ^e   Force, Lluís ^f   Llibre, Josep M ^g   Vilaró, Josep ^h   Dalmau, David ⁱ   Cucurull, Josep ^j   Mascaró, Jaume ^k   Masabeu, Angels ^l   Pérez Álvarez, Núria ^a   Puig, Jordi ^a   Cinquegrana, Denise ^a   Clotet, Bonaventura ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c Parc Taulí Health Corporation   (Spain)

^d HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL DE MATARÓ   (Spain)

^g Hospital de Calella   (Spain)

^h HOSPITAL GENERAL DE VIC   (Spain)

ⁱ HOSPITAL MÚTUA DE TERRASSA   (Spain)

^j HOSPITAL DE FIGUERES   (Spain)

^k Hospital Trueta   (Spain)

^l Hospital de Palamos   (Spain)

^m HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; VIRUS RNA;

ACUTE HEPATITIS; ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; CLINICAL TRIALS; CROSS-OVER STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33646123516     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.321     Document Type: Article

References (31)

1. Martinez E, Arnaiz J, Podzamczer D, Dalmau D, Ribera E, Domingo P, et al.: Substitution of nevirapine, efavirenz or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003;349:1036-1046.
2. Negredo E, Cruz L, Paredes R, Ruiz L, Fumaz C, Bonjoch A, et al.: Virological, immunological and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with long-lasting viral suppression. Clin Infect Dis 2002;34:504-510.
3. Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, et al.: A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (COMBINE study). Antiviral Ther 2002;7:81-90.
4. Lange J: Efficacy and durability of nevirapine in antiretroviral drugs naive patients. J Acquir Immune Defic Syndr 2003;34:S40-52.
5. Martinez E, Blanco JL, Arnaiz J, Perez-Cuevas J, Mocroft A, Cruceta A, et al.: Hepatotoxicity in HIV-1 infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001;15:1261-1268.
6. Kontorinis N and Dieterich DT: Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 2003;23:173-181.
7. Sulkowski MS, Thomas DL, Chaisson RE, and Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
8. Sulkowski M, Thomas D, Mehta S, Chaisson R, and Moore R: Hepatotoxicity associated with nevirapine or efavirenz containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology 2002;35:182-189.
9. Kresina TF, Flexner CW, Sinclair J, Correira MA, Stapleton JT, Adeniyi-Jones S, et al.: Alcohol use and HIV pharmacotherapy. AIDS Res Hum Retroviruses 2002;18:757-770.
10. Martin A, Cameron P, Nolan D, James I, Keller J, Phillips E, et al.: Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*01 and higher CD4+ T cell counts. In: XV International AIDS Conference, Bangkok, Thailand, 2004. Abstract LbOrB13. International AIDS Society, Stockholm.
11. Kramer F, Stek A, Du WB, and Kovaks A: Nevirapine tolerability in HIV-infected women in pregnancy, 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, CA (abstract 923).
12. Bershoff-Matcha SJ, Mundy LM, and Henry JV: Adverse events to nevirapine therapy during pregnancy. 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, CA (abstract 939).
13. Bersoff-Matcha S, Miller W, Aberg J, van der Horst C, Hamrick J, Powderly W, et al.: Sex differences in nevirapine rash. Clin Infect Dis 2001;32:124-129.
14. Hitti J, Frenkel L, Huang S, Wei L, Stevens L, Watts H, et al.: Toxicity with continuous nevirapine in pregnancy. Results from PACTG 1022. 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco CA (abstract 938).
15. Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, et al.: Mortality for liver disease in patients with HIV infection: A cohort study. J Acquir Immune Defic Syndr 2000;24:211-217.
16. Negredo E, Moltó J, Muñoz J, Pedrol E, Ribera E, Viciana P, et al.: Safety and efficacy of once-daily dose didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. Antiviral Ther 2004;9:335-342.
17. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, et al.: Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet 2004;17:1253-1263.
18. Parienti J, Massari V, Descamps D, Vabret, Bouvet E, Larouze B, et al.: Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004;38:1311-1316.
19. AIDS Clinical Trial Group: Table of grading severity of adult adverse experiences. Division of AIDS, National Institute of Allergy and Infectious Disease, Rockville, MD, 1996.
20. Palmon R, Koo B, Shoultz D, and Dieterich D: Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002;29:340-345.
21. Bonnet F, Lawson-Ayayi S, Thiébaut R, Ramanampamonjy R, Lacoste D, Bernard N, et al.: A cohort of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999. Clin Infect Dis 2002;35:1231-1237.
22. Murphy RL: Defining the toxicity profile of nevirapine and other antiretroviral drugs. J Acquir Immune Defic Syndr 2003;34:S15-20.
23. Dieterich D, Becker S, Fusco J, Balu R, Most BM, Stern J, et al.: Low incidence of grade III/IV hepatotoxicity in first HAART observations from 1,237 patients followed for one year. In: XIV International AIDS Conference, Barcelona, Spain, 2002. Poster 4534. International AIDS Society, Stockholm.
24. Martin-Carbonero L, Núñez M, Rios P, Perez-Olmeda M, Gonzalez-Lahoz J, and Soriano V: Liver injury after beginning antiretroviral therapy on HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. AIDS 2002;16:1423-1425.
25. Vento S, Garofano T, Renzini C, Casali F, Ferraro T, and Concia E: Enhancement of hepatitis C virus replication and liver damage in HTV-co-infected patients on antiretroviral combination therapy. AIDS 1998;12:116-117.
26. Lamson M, Maldonado S, Hutman H, et al.: The effects of underlying renal or hepatic dysfunction on the pharmacokinetics of nevirapine. In: 8th International Conference on AIDS, Durban, South Africa, 2000. Abstract TuPeb3301. International AIDS Society, Stockholm.
27. Gonzalez de Requena D, Núñez M, Jimenez-Nacher I, Gonzalez-Lahoz J, and Soriano V: Liver toxicity caused by nevirapine. AIDS 2002;16:290-291.
28. Fontas E, Van Leth F, Sabin A, Friis-Meller N, Rickenbach M, d'Arminio Monforte A, et al.: Lipid profile in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004;189:1056-1074.
29. van der Valk M, Kasatelein J, Murphy R, van Leth F, Katlama C, Horban A, et al.: Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001;15:2407-2414.
30. Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balaguer M, et al.: Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr 2001;27:229-236.
31. Van Leth F, Phanuphak P, Gazzard B, Cahn P, Wood R, Bloch M, et al.: Lipid changes in a randomized comparative trial of a firstline antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine (2NN study). In: 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003, Boston, MA. Abstract 752. Foundation for Retrovirology and Human Health, Alexandria, VA.